B+
Bull case
25%
Probability
Target price
$32.00
+33.4% vs current
KMTS
Kestra MedicalBNasdaq / Health Care Equipment & Services
Last Price
At close
2026-07-18
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
50%
Probability
Target price
$27.00
+12.6% vs current
B-
Bear case
25%
Probability
Target price
$18.00
-24.9% vs current
AI sentiment snapshot
Latest data as of 2026-07-17
Recent news sentiment (30D)
+30.0
Positive
Company
-
Unavailable
Macro
+30.0
Positive
Pulse
-
Unavailable
Sentiment proxy
+52.3
Score
AI commentary
The earnings release tone is constructive, but the evidence is concentrated in company/SEC reporting. The July 16 anchor price was $23.98; analyst revision data, options positioning, short interest, employee sentiment, and a verified post-print reaction are unavailable, so conviction remains moderate and monitoring-oriented.
RankAlpha Sentiment Codex - 2026-07-17
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-07-14eventFY26 results and FY27 revenue guideHigh impact
Q4 revenue rose 66% to $28.6 million, gross margin expanded to 54.8%, and FY27 revenue guidance was set at $137 million, up 44% from FY26. [#SEC-8K-2026-07-14]
2026-10-15eventProduct and collaboration executionHigh impact
Management cited progress on FDA post-approval study results, an algorithm update, commercial expansion, and a strategic collaboration with Biobeat; the packet does not provide enough detail to assign a high-conviction milestone value. [#SEC-8K-2026-07-14]
2027-07-17catalystPrescription and market-share expansionHigh impact
Q4 ASSURE prescriptions increased 63% to 6,357; management attributed growth primarily to higher market share and wearable cardioverter-defibrillator market expansion. [#SEC-8K-2026-07-14]
Recommendation
N/A
No formal recommendation provided.
As of 2026-07-17 • Updated nightlySource: Internal modelMethodology